SDRIFE und bullöse Reaktion nach Behandlung mit Enfortumab Vedotin plus Pembrolizumab: Fallserie
Juan J. Lluch-Galcerá
Department of Dermatology, Hospital Universitari Germans Trials i Pujol, Institut d'Investigació GermansTrias i Pujol, Universitat Autònoma de Barcelona, Departament de Medicina, Badalona, Barcelona, Spain
Search for more papers by this authorNerea Manzanares-Oliver
Department of Dermatology, Hospital del Mar, Institut Mar d'Investigacions Mèdiques, Universitat Autònoma de Barcelona (UAB) and Universitat Pompeu Fabra (UPF), Barcelona, Spain
Search for more papers by this authorManel Martinez-Molina
Department of Dermatology, Hospital Universitari Germans Trials i Pujol, Institut d'Investigació GermansTrias i Pujol, Universitat Autònoma de Barcelona, Departament de Medicina, Badalona, Barcelona, Spain
Search for more papers by this authorLorena Valdivieso
Department of Pathology, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
Search for more papers by this authorAram Boada
Department of Dermatology, Hospital Universitari Germans Trials i Pujol, Institut d'Investigació GermansTrias i Pujol, Universitat Autònoma de Barcelona, Departament de Medicina, Badalona, Barcelona, Spain
Search for more papers by this authorSònia Segura
Department of Dermatology, Hospital del Mar, Institut Mar d'Investigacions Mèdiques, Universitat Autònoma de Barcelona (UAB) and Universitat Pompeu Fabra (UPF), Barcelona, Spain
Search for more papers by this authorRoger Rovira
Department of Dermatology, Hospital del Mar, Institut Mar d'Investigacions Mèdiques, Universitat Autònoma de Barcelona (UAB) and Universitat Pompeu Fabra (UPF), Barcelona, Spain
Search for more papers by this authorRamón M Pujol
Department of Dermatology, Hospital del Mar, Institut Mar d'Investigacions Mèdiques, Universitat Autònoma de Barcelona (UAB) and Universitat Pompeu Fabra (UPF), Barcelona, Spain
Search for more papers by this authorCorresponding Author
Ane Jaka
Department of Dermatology, Hospital Universitari Germans Trials i Pujol, Institut d'Investigació GermansTrias i Pujol, Universitat Autònoma de Barcelona, Departament de Medicina, Badalona, Barcelona, Spain
Korrespondenzanschrift
Ane Jaka, MD, PhD, Department of Dermatology, Hospital Universitari Germans Trias i Pujol., C/ Carretera de Canyet, s/n, 08916 Badalona, Barcelona.
Email: [email protected]
Search for more papers by this authorJuan J. Lluch-Galcerá
Department of Dermatology, Hospital Universitari Germans Trials i Pujol, Institut d'Investigació GermansTrias i Pujol, Universitat Autònoma de Barcelona, Departament de Medicina, Badalona, Barcelona, Spain
Search for more papers by this authorNerea Manzanares-Oliver
Department of Dermatology, Hospital del Mar, Institut Mar d'Investigacions Mèdiques, Universitat Autònoma de Barcelona (UAB) and Universitat Pompeu Fabra (UPF), Barcelona, Spain
Search for more papers by this authorManel Martinez-Molina
Department of Dermatology, Hospital Universitari Germans Trials i Pujol, Institut d'Investigació GermansTrias i Pujol, Universitat Autònoma de Barcelona, Departament de Medicina, Badalona, Barcelona, Spain
Search for more papers by this authorLorena Valdivieso
Department of Pathology, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
Search for more papers by this authorAram Boada
Department of Dermatology, Hospital Universitari Germans Trials i Pujol, Institut d'Investigació GermansTrias i Pujol, Universitat Autònoma de Barcelona, Departament de Medicina, Badalona, Barcelona, Spain
Search for more papers by this authorSònia Segura
Department of Dermatology, Hospital del Mar, Institut Mar d'Investigacions Mèdiques, Universitat Autònoma de Barcelona (UAB) and Universitat Pompeu Fabra (UPF), Barcelona, Spain
Search for more papers by this authorRoger Rovira
Department of Dermatology, Hospital del Mar, Institut Mar d'Investigacions Mèdiques, Universitat Autònoma de Barcelona (UAB) and Universitat Pompeu Fabra (UPF), Barcelona, Spain
Search for more papers by this authorRamón M Pujol
Department of Dermatology, Hospital del Mar, Institut Mar d'Investigacions Mèdiques, Universitat Autònoma de Barcelona (UAB) and Universitat Pompeu Fabra (UPF), Barcelona, Spain
Search for more papers by this authorCorresponding Author
Ane Jaka
Department of Dermatology, Hospital Universitari Germans Trials i Pujol, Institut d'Investigació GermansTrias i Pujol, Universitat Autònoma de Barcelona, Departament de Medicina, Badalona, Barcelona, Spain
Korrespondenzanschrift
Ane Jaka, MD, PhD, Department of Dermatology, Hospital Universitari Germans Trias i Pujol., C/ Carretera de Canyet, s/n, 08916 Badalona, Barcelona.
Email: [email protected]
Search for more papers by this authorJuan J. Lluch-Galcerá und Nerea Manzanares-Oliver haben gleichermaßen zu dieser Arbeit beigetragen.
LITERATUR
- 1Lacouture M, Patel A, Rosenberg J, et al. Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin. Oncologist. 2022; 27: e223-e232.
- 2Penny C, Quow K, Rundle C, et al. Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin. Br J Dermatol. 2022; 187: 126-127.
- 3Hirotsu KE, Rana J, Wang JY, et al. Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma. J Am Acad Dermatol. 2021; 85(6): 1610-1611.
- 4Dobry A, Virgen C, Hosking AM, et al. Cutaneous reactions with enfortumab vedotin: A case series and review of the literature. JAAD Case Rep. 2021; 14: 7-9.
- 5 World Health Organization. Vigiaccess.org [Internet]. Available from: https://www.vigiaccess.org [Last accessed January 24, 2024].
- 6Buhl T, Forkel S. The flood of drug allergy cases. J Dtsch Dermatol Ges. 2022; 20(10): 1283-1284.
- 7Mössner R. Severe side effects of targeted therapies. J Dtsch Dermatol Ges. 2022; 20(6): 747-748.
- 8O'Donnell PH, Milowsky MI, Petrylak DP, et al. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol. 2023; 41(25): 4107-4117.
- 9Pospischil I, Hoetzenecker W. Drug eruptions with novel targeted therapies – immune checkpoint and EGFR inhibitors. J Dtsch Dermatol Ges. 2021; 19(11): 1621-1643.
